Onchocerciasis

Case-control study Mahenge, Tanzania.

Year Started: 2021

HLA typing among cases and controls of onchocerciasis-associated epilepsy cases.



Access:
Open to applicants
Type:
Case-control
Status:
Completed
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
Biomarker datasets 0 - 3 months
Clinical records 0 - 3 months
Genomic datasets 0 - 3 months
Survey data 0 - 3 months
Participant Ethnicity 0 - 3 months
Microbiological results 0 - 3 months


Both sexes

Child (6 - 12 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Microscopic Assessment % of Sample Set
Serum -85°C to -60°C Not applicable 75% -99%
Dried whole blood -85°C to -60°C Not applicable 75% -99%


Both sexes

Adolescent (12 - 18 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Microscopic Assessment % of Sample Set
Serum -85°C to -60°C Not applicable 75% -99%
Dried whole blood -85°C to -60°C Not applicable 75% -99%


Both sexes

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Microscopic Assessment % of Sample Set
Serum -85°C to -60°C Not applicable 100%
Dried whole blood -85°C to -60°C Not applicable 100%

Onchocerciasis

Single versus Multiple Dose Ivermectin Regimen in Onchocerciasis-Infected Persons with Epilepsy Treated with Phenobarbital: A Randomized Clinical Trial in the Democratic Republic of Congo

Year Started: 2016

In October 2017, a 12-month clinical trial was initiated in rural Democratic Republic of Congo. PWE with onchocerciasis-associated epilepsy experiencing ≥2 seizures/month were randomly allocated to receive, over a one-year period, ivermectin once or thrice (group 1), while other onchocerciasis-infected PWE (OIPWE) were randomized to ivermectin twice or thrice (group 2). All participants also received anti-epileptic drugs.



Access:
Open to applicants
Type:
Clinical Trial
Status:
Completed
Consent restrictions:
Genetic analysis restriction


Associated Data Type Procurement Timeframe
Biomarker datasets 0 - 3 months
Clinical records 0 - 3 months
Followup records 0 - 3 months
Freezer temperature logs 0 - 3 months
Quality indicators 0 - 3 months
Treatment records 0 - 3 months
Participant Ethnicity 0 - 3 months


Both sexes

Child (6 - 12 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Microscopic Assessment % of Sample Set
Serum -85°C to -60°C Not applicable 100%


Both sexes

Adolescent (12 - 18 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Microscopic Assessment % of Sample Set
Serum -85°C to -60°C Not applicable 100%


Both sexes

Adult (> 40 years)

1 - 10 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Microscopic Assessment % of Sample Set
Serum -85°C to -60°C Not applicable 100%

Onchocerciasis

Pregnancy, Onchocerca volvulus infection and ivermectin use: a cross-sectional study

Year Started: 2020

Pregnant and post-partum women and their partners will be screened for O. volvulus infection and other NTDs



Access:
Open to applicants
Type:
Cross-sectional
Status:
Not-started
Consent restrictions:
No restrictions


Associated Data Type Procurement Timeframe
There is no associated data for this collection.


Both sexes

Young adult (18 - 40 years)

101 - 500 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Microscopic Assessment % of Sample Set
Serum -35°C to -18°C Not applicable 100%


Both sexes

Young adult (18 - 40 years)

11 - 100 donors

Material Type Extraction Procedure Storage Temperature Preservation Type Microscopic Assessment % of Sample Set
Serum -35°C to -18°C Not applicable 100%